Outcomes in COVID-19 antiandrogen studies
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 77%
0.23 [0.08-0.66]
recov. time
8 (n)
262 (n)
Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 62%
0.38 [0.18-0.82]
no recov.
7/44
18/43
Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment 68%
0.32 [0.17-0.59]
7/52
18/305
68% improvement Goren 81%
0.19 [0.03-1.28]
ICU
1/12
17/36
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 81%
0.19 [0.03-1.28]
1/12
17/36
81% improvement Montopoli 75%
0.25 [0.09-0.76]
severe case
Improvement, RR [CI] Treatment Control Bennani 95%
0.05 [0.00-2062]
death
0/4
18/114
Lazzeri -23%
1.23 [0.81-1.87]
death/ICU
Tau​2 ​ = 0.33; I​2 ​ = 24.1%
Prophylaxis 15%
0.85 [0.30-2.45]
0/4
18/114
15% improvement All studies 59%
0.41 [0.17-0.99]
8/68
53/455
59% improvement 6 antiandrogen COVID-19 studies c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.64; I​2 ​ = 70.2%; Z = 1.98
Effect extraction pre-specified
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Goren 81%
0.19 [0.03-1.28]
ICU
1/12
17/36
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 81%
0.19 [0.03-1.28]
1/12
17/36
81% improvement Montopoli 75%
0.25 [0.09-0.76]
severe case
Improvement, RR [CI] Treatment Control Bennani 95%
0.05 [0.00-2062]
death
0/4
18/114
Lazzeri -23%
1.23 [0.81-1.87]
death/ICU
Tau​2 ​ = 0.33; I​2 ​ = 24.1%
Prophylaxis 15%
0.85 [0.30-2.45]
0/4
18/114
15% improvement All studies 48%
0.52 [0.15-1.83]
1/16
35/150
48% improvement 4 antiandrogen COVID-19 studies after exclusions c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.75; I​2 ​ = 49.2%; Z = 1.01
Effect extraction pre-specified
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Bennani 95%
0.05 [0.00-2062]
0/4
18/114
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Prophylaxis 95%
0.05 [0.00-2062]
0/4
18/114
95% improvement All studies 95%
0.05 [0.00-2062]
0/4
18/114
95% improvement 1 antiandrogen COVID-19 mortality result c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.55
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Goren 81%
0.19 [0.03-1.28]
1/12
17/36
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 81%
0.19 [0.03-1.28]
1/12
17/36
81% improvement Bennani -119%
2.19 [0.37-12.9]
1/4
13/114
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Prophylaxis -119%
2.19 [0.37-12.9]
1/4
13/114
-119% improvement All studies 34%
0.66 [0.06-7.28]
2/16
30/150
34% improvement 2 antiandrogen COVID-19 ICU results c19early.com/aa Dec 5, 2021
Tau​2 ​ = 2.11; I​2 ​ = 70.5%; Z = 0.34
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Bennani 25%
0.75 [0.28-2.02]
hosp.
2/4
76/114
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Prophylaxis 25%
0.75 [0.28-2.02]
2/4
76/114
25% improvement All studies 25%
0.75 [0.28-2.02]
2/4
76/114
25% improvement 1 antiandrogen COVID-19 hospitalization result c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.57
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Goren 81%
0.19 [0.03-1.28]
ICU
1/12
17/36
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 81%
0.19 [0.03-1.28]
1/12
17/36
81% improvement Montopoli 75%
0.25 [0.09-0.76]
severe case
Improvement, RR [CI] Treatment Control Bennani 95%
0.05 [0.00-2062]
death
0/4
18/114
Lazzeri -23%
1.23 [0.81-1.87]
death/ICU
Tau​2 ​ = 0.33; I​2 ​ = 24.1%
Prophylaxis 15%
0.85 [0.30-2.45]
0/4
18/114
15% improvement All studies 48%
0.52 [0.15-1.83]
1/16
35/150
48% improvement 4 antiandrogen COVID-19 serious outcomes c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.75; I​2 ​ = 49.2%; Z = 1.01
Effect extraction pre-specified
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 77%
0.23 [0.08-0.66]
recov. time
8 (n)
262 (n)
Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 62%
0.38 [0.18-0.82]
no recov.
7/44
18/43
Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment 68%
0.32 [0.17-0.59]
7/52
18/305
68% improvement All studies 68%
0.32 [0.17-0.59]
7/52
18/305
68% improvement 2 antiandrogen COVID-19 recovery results c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 3.62
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Montopoli 75%
0.25 [0.09-0.65]
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Prophylaxis 75%
0.25 [0.09-0.65]
75% improvement All studies 75%
0.25 [0.09-0.67]
75% improvement 1 antiandrogen COVID-19 case result c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 2.75
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 38%
0.62 [0.42-0.91]
viral time
8 (n)
262 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment 38%
0.62 [0.42-0.91]
0/8
0/262
38% improvement All studies 38%
0.62 [0.42-0.91]
0/8
0/262
38% improvement 1 antiandrogen COVID-19 viral clearance result c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 2.43
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani (DB RCT) 62%
0.38 [0.18-0.82]
no recov.
7/44
18/43
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment 62%
0.38 [0.18-0.82]
7/44
18/43
62% improvement All studies 62%
0.38 [0.18-0.82]
7/44
18/43
62% improvement 1 antiandrogen COVID-19 Randomized Controlled Trials c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 2.48
Effect extraction pre-specified
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani (DB RCT) 62%
0.38 [0.18-0.82]
no recov.
7/44
18/43
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment 62%
0.38 [0.18-0.82]
7/44
18/43
62% improvement Goren 81%
0.19 [0.03-1.28]
ICU
1/12
17/36
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 81%
0.19 [0.03-1.28]
1/12
17/36
81% improvement Montopoli 75%
0.25 [0.09-0.76]
severe case
Improvement, RR [CI] Treatment Control Bennani 95%
0.05 [0.00-2062]
death
0/4
18/114
Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Prophylaxis 76%
0.24 [0.03-1.71]
0/4
18/114
76% improvement All studies 67%
0.33 [0.17-0.65]
8/60
53/193
67% improvement 4 antiandrogen COVID-19 peer reviewed trials c19early.com/aa Dec 5, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 3.24
Effect extraction pre-specified
Favors antiandrogen
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 77%
0.23 [0.08-0.66]
recov. time
8 (n)
262 (n)
Improvement, RR [CI] Treatment Control Cadegiani 83%
0.17 [0.06-0.51]
recov. time
8 (n)
262 (n)
Cadegiani 38%
0.62 [0.42-0.91]
viral time
8 (n)
262 (n)
Cadegiani (DB RCT) 62%
0.38 [0.18-0.82]
no recov.
7/44
18/43
Cadegiani (DB RCT) 44%
0.56 [0.40-0.79]
recov. time
44 (n)
43 (n)
Cadegiani (DB RCT) 40%
0.60 [0.44-0.81]
recov. time
44 (n)
43 (n)
Goren 81%
0.19 [0.03-1.28]
ICU
1/12
17/36
Goren 86%
0.14 [0.02-0.94]
ICU
1/12
38/65
Goren -50%
1.50 [0.15-15.1]
death
1/12
2/36
Goren -35%
1.35 [0.17-11.1]
death
1/12
4/65
Montopoli 75%
0.25 [0.09-0.76]
severe case
Montopoli 75%
0.25 [0.09-0.65]
cases
Bennani 95%
0.05 [0.00-2062]
death
0/4
18/114
Bennani -119%
2.19 [0.37-12.9]
ICU
1/4
13/114
Bennani 25%
0.75 [0.28-2.02]
hosp.
2/4
76/114
Bennani 8%
0.92 [0.16-5.15]
severe case
1/4
31/114
Lazzeri -23%
1.23 [0.81-1.87]
death/ICU
antiandrogen COVID-19 outcomes c19early.com/aa Dec 5, 2021
Favors antiandrogen
Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
